Dermatitis: Clinical Trials

53 trials for Dermatitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

53 terminated. 53 Phase 2, 8 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 253Terminated 53
Phase 18Terminated 8
Phase 33Terminated 3

Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis

Trials (filtered) newest first · largest first

All 53 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
Dupilumab, Placebo, IBI356 - Atopic Dermatitis
Phase 2TerminatedInnovent Biologics (Suzhou) Co. Ltd.182025-12-312026-10-27
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
Dupilumab, JNJ-95475939, Placebo - Dermatitis, Atopic
Phase 2TerminatedJanssen Research & Development, LLC2562025-02-262026-07-31
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.
GSK1070806, Placebo - Dermatitis, Atopic
Phase 2TerminatedGlaxoSmithKline792024-06-052026-06-16
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
GSK1070806, Placebo - Dermatitis, Atopic
Phase 2TerminatedGlaxoSmithKline1612023-11-162026-06-03
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
SAR444656 (KT-474), Placebo - Atopic Dermatitis
Phase 2TerminatedSanofi702023-11-092026-11-03
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
Placebo, IMG-007 - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
Phase 1 / Phase 2TerminatedInmagene LLC132023-08-092025-11-06
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
PF-07038124, Placebo Ointment - Seborrheic Dermatitis, Papulopustular Rosacea
Phase 2TerminatedIcahn School of Medicine at Mount Sinai322023-07-192026-08-14
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
LY3454738, Placebo - Atopic Dermatitis
Phase 2TerminatedEli Lilly and Company2342023-06-212025-12-02
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
Dermaprazole 1%, Dermaprazole 2% - Radiation Dermatitis, Breast Cancer
Phase 1 / Phase 2TerminatedBaylor College of Medicine32023-04-242026-02-17
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified
Phase 2 / Phase 3TerminatedPfizer582023-01-182025-05-08
A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis
BMX-010, Placebo - Atopic Dermatitis
Phase 2TerminatedBioMimetix JV, LLC1032023-01-082024-04-18
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
AK002, Placebo - Atopic Dermatitis
Phase 2TerminatedAllakos Inc.1312022-06-272024-10-15
Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation
Application of Tralokinumab - Atopic Dermatitis
Phase 2 / Phase 3TerminatedUniversity of Zurich242022-06-152026-02-06
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
RPT193, Placebo - Atopic Dermatitis
Phase 2TerminatedRAPT Therapeutics, Inc., a member of the GSK plc group of companies2292022-06-072026-03-23
A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials
EDP1815 - Atopic Dermatitis
Phase 2TerminatedEvelo Biosciences, Inc.2872022-06-062023-09-07
Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
Broncho-Vaxom, Placebo - Atopic Dermatitis
Phase 2TerminatedOM Pharma SA632021-12-202023-08-08
Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel
DBI-001, Aqueous gel - Atopic Dermatitis
Phase 2TerminatedDermBiont, Inc.102021-10-062023-11-08
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
Placebo, AK120 - Atopic Dermatitis
Phase 2TerminatedAkesobio Australia Pty Ltd792021-09-302025-02-26
A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Bermekimab, Placebo - Dermatitis, Atopic
Phase 2TerminatedJanssen Research & Development, LLC62021-09-022023-05-24
Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study
FB-401 - Atopic Dermatitis
Phase 2TerminatedForte Biosciences, Inc.362021-06-022021-10-28

Showing 20 of 53. Sign in to see all of them.

Narrower conditions

Dermatitis, Atopic (45)  ·  Eczema (14)  ·  Breast Neoplasms (4)  ·  Immune System Diseases (4)  ·  Pruritus (4)  ·  Skin Diseases (4)  ·  Lymphoma, Follicular (3)  ·  Radiodermatitis (3)  ·  Hand-Foot Syndrome (2)  ·  Psoriasis (2)  ·  Stevens-Johnson Syndrome (2)  ·  Alopecia (1)  ·  Dermatitis, Seborrheic (1)  ·  Inflammation (1)

Broader conditions

Skin and Connective Tissue Diseases (53)  ·  Skin Diseases (49)  ·  Hypersensitivity (47)  ·  Skin Diseases, Eczematous (46)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (45)  ·  Genetic Diseases, Inborn (45)  ·  Hypersensitivity, Immediate (45)  ·  Skin Diseases, Genetic (45)  ·  Immune System Diseases (43)  ·  Neoplasms (8)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Signs and Symptoms (6)  ·  Skin Manifestations (5)  ·  Breast Diseases (4)

Interventions

dupilumab (4)  ·  GSK1070806 (2)  ·  bermekimab (2)  ·  itepekimab (2)  ·  8,11,14-Eicosatrienoic Acid (1)  ·  AK002 (1)  ·  BANG polymer gel (1)  ·  Brimonidine Tartrate (1)  ·  Broncho-Vaxom (1)  ·  Clobetasol (1)  ·  Fibroblast Growth Factor 7 (1)  ·  Lamotrigine (1)  ·  Oils (1)  ·  Petrolatum (1)  ·  Therapeutics (1)

Sponsors

GlaxoSmithKline (3)  ·  Janssen Research & Development, LLC (3)  ·  Regeneron Pharmaceuticals (3)  ·  DermBiont, Inc. (2)  ·  Eli Lilly and Company (2)  ·  Lakefront Biotherapeutics NV (2)  ·  Novartis Pharmaceuticals (2)  ·  Akesobio Australia Pty Ltd (1)  ·  Allakos Inc. (1)  ·  Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1)  ·  Amgen (1)  ·  Arjil Pharmaceuticals LLC (1)  ·  Asana BioSciences (1)  ·  AstraZeneca (1)  ·  Baylor College of Medicine (1)

Countries

United States (39)  ·  Germany (18)  ·  Poland (18)  ·  Canada (17)  ·  Japan (12)  ·  Czechia (9)  ·  Spain (9)  ·  South Korea (7)  ·  Hungary (6)  ·  United Kingdom (6)  ·  Argentina (5)  ·  Australia (5)  ·  France (5)  ·  Taiwan (5)  ·  Bulgaria (4)

Top investigators

Alex Zvulunov, Prof (1)  ·  Avner Shemer, Prof (1)  ·  Ben Ehst, PhD (1)  ·  Benjamin Ungar, MD (1)  ·  Chin Lee, MD, MPH (1)  ·  Daisy Blanco, MD (1)  ·  Dalia Gilat, Dr. (1)  ·  Daniel A Hamstra, MD, PhD (1)  ·  David Zammit, Ph.D. (1)  ·  Douglas Maslin, MD (1)

Results publications

PMID 39077906, PMID 18645136

NIH funding

2018 (5), 2023 (3), 2017 (1)